SAN DIEGO, April 15, 2019 /PRNewswire-PRWeb/ -- Calidi Biotherapeutics, Inc., a clinical?stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that Allan Camaisa, Calidi Biotherapeutics CEO, and San Diego based serial entrepreneur, was interviewed by San Diego's local news station KUSI. The interview was part of the TV station's focus on local San Diego Biotech organizations and their race to cure cancer. Calidi Biotherapeutics is currently developing a novel immunotherapy approach utilizing an oncolytic vaccinia virus delivered via cell-based therapeutic platforms.
Mr. Camaisa shared the progress that Calidi Biotherapeutics has made, and what the future holds for the San Diego-based biotech. Mr. Camaisa also shared that his passion for finding a cure for cancer is due to the loss of his father to the disease.
"During my Father's illness, I searched for a solution, a clinical trial, anything. Unfortunately, there was nothing at the time that could help my father," said Allan J. Camaisa, CEO and Chairman of Calidi Biotherapeutics. "Fast forward to Calidi, and our patented technology: it teaches a patient's immune system to recognize, fight and kill cancer cells. In our 26 patient safety study, no one experienced any significant side effects."
Interview Highlights:
SOURCE Calidi Biotherapeutics
Advertisement
Mr. Camaisa shared the progress that Calidi Biotherapeutics has made, and what the future holds for the San Diego-based biotech. Mr. Camaisa also shared that his passion for finding a cure for cancer is due to the loss of his father to the disease.
Advertisement
"During my Father's illness, I searched for a solution, a clinical trial, anything. Unfortunately, there was nothing at the time that could help my father," said Allan J. Camaisa, CEO and Chairman of Calidi Biotherapeutics. "Fast forward to Calidi, and our patented technology: it teaches a patient's immune system to recognize, fight and kill cancer cells. In our 26 patient safety study, no one experienced any significant side effects."
Interview Highlights:
- Immuno-oncology, the current problem that everyone is trying to solve is keeping the patient's blood complement and immune system from wiping out virus-based solutions.
- How Calidi is solving this issue, through its patented approach.
- The outcome of Calidi's 26 patient safety study.
- Future partnerships that Calidi is currently exploring.
SOURCE Calidi Biotherapeutics
